Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

tigenix n.v. - karakterizirane održive autologne stanice hrskavice eksprimiraju ex vivo eksprimirajući specifične markere proteine - bolesti hrskavice - ostali lijekovi za poremećaje mišićno-koštanog sustava - popravak oštećenja jednog simptomatsko hrskavice kondila bedrene koljena (international hrskavice repair society [icrs] stupnja iii ili iv) u odraslih. polaznik asimptomatskih lezija hrskavice (ПВК klase i ili ii) mogu biti prisutni. demonstracija efikasnosti temelji se na randomizirana kontrolirana studija o proceni efikasnosti chondrocelect u bolesnika s porazom od 1 do 5 cm2.

Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - poremećaj erekcije - urologicals - liječenje erektilne disfunkcije. da bi tadalafil bio učinkovit, potrebna je seksualna stimulacija. cialis nije indiciran za primjenu kod žena.

Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - pemetreksed dinatrij hemipentahidrat - carcinoma, non-small-cell lung; mesothelioma - antineoplastična sredstva - malignant pleural mesothelioma ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. ciambra prikazan kao monoterapija za liječenje местнораспространенного ili метастатического немелкоклеточного raka pluća, druge, nego pretežno плоскоклеточного гистологии kod pacijenata, bolest kojoj se ne прогрессировало odmah nakon kemoterapije платиносодержащей. ciambra prikazan kao monoterapija za drugu liniju terapije kod bolesnika sa lokalno-uobičajena ili metastatskih немелкоклеточным raka pluća nego drugi uglavnom плоскоклеточной гистологией.

Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

takeda manufacturing austria ag - c1 inhibitor (humani) - angioedemas, nasljedni - c1-inhibitor; u plazmi derivata, lijekova koji se koriste u потомственное angioedema - liječenje i pre-postupak prevencije angioedemskih napada u odraslih, adolescenata i djece (2 godine i više) s nasljednim angioedemom (hae). rutinski profilaksa angioedema, udara kod odraslih, djece i adolescenata (sa 6 godina); kod teških i рецидивирующих udara nasljedni ангионевротического edema (he), koji ne podnose ili nedovoljno zaštićeni usmeno upozorenje liječenje, ili u pacijenata koji su neadekvatno upravlja, kada se ponavljaju akutno liječenje.

Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotska sredstva - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). porastom segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. za više informacija, molimo pogledajte odjeljak 5.

Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

biogaran - clopidogrel (as hydrogen sulfate) - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - sprječavanje атеротромботических događaja klopidogrel prikazan:odrasli pacijenti koji pate инфарктом miokarda (od nekoliko dana do manje od 35 dana), ishemijski moždani udar (od 7 dana prije manje od 6 mjeseci) ili instaliranim bolest perifernih arterija.

Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

hcs bvba  - clopidogrel (as hydrochloride) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotska sredstva - sekundarne prevencije атеротромботических eventsclopidogrel prikazan:odrasli pacijenti koji pate инфарктом miokarda (od nekoliko dana do manje od 35 dana), ishemijski moždani udar (od 7 dana prije manje od 6 mjeseci) ili instaliranim bolest perifernih arterija. odraslih pacijenata oboljelih od akutne коронарным sindroma:bez elevacije segmenta st akutna koronarna sindrom (nestabilna angina, ili ne-q-инфарктом miokarda), uključujući i bolesnike koji su patili ugradnje stenta nakon чрескожного koronarne intervencije, u kombinaciji s ацетилсалициловой kiselinom (ask). porastom segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. sprječavanje атеротромботических i тромбоэмболических događaja kada фибрилляции fibrillationin odraslih pacijenata s фибрилляцией vrlo značajan, koje imaju najmanje jedan faktor rizika za razvoj srčanih događaja, nisu pogodni za liječenje антагонистами vitamina k (ВКА) i koji imaju nizak rizik od krvarenja, клопидогрел prikazan u kombinaciji s ask za prevenciju атеротромботических i тромбоэмболических događaja, uključujući i moždani udar.  for further information please refer to section 5.

Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

krka, d.d., novo mesto - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - Клопидогрел prikazan odrasle za prevenciju атеротромботических događaja:pacijenti koji pate инфарктом miokarda (od nekoliko dana do manje od 35 dana), ishemijski moždani udar (od 7 dana prije manje od 6 mjeseci) ili instaliranim bolest perifernih arterija.

Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.